间充质基质细胞治疗急性肾损伤:过去十年的进展
本文综述了过去十年间充质基质细胞(MSC)治疗急性肾损伤(AKI)的进展。大量动物模型研究强化了MSC减轻无菌性和脓毒症相关AKI肾损伤的证据,并揭示了其体内命运和作用机制;但人体早期临床试验数量有限,仅显示安全性,未显现明确疗效信号。
要点
- 临床前研究显示MSC可减轻无菌性和脓毒症相关AKI的肾损伤。
- MSC在AKI中的体内命运和作用机制获得新认识。
- 人体早期试验仅显示安全性,疗效信号不强。
核心结论
- 过去十年临床前研究显著加强了MSC治疗AKI的转化路径,但临床证据仍限于少量早期试验,安全性可接受而疗效信号不强。
研究设计与样本
- 综述总结过去十年MSC治疗AKI的临床前与临床研究进展。
主要发现
- 更多动物模型研究证实系统或局部递送MSC可改善无菌性和脓毒症相关AKI的肾损伤。
- 临床前研究提供了MSC在AKI等炎症状态下体内命运和作用机制的新见解。
- 人体MSC治疗AKI或脓毒症相关AKI的临床经验仅限于少量早期临床试验,显示安全性但未呈现强疗效信号。
临床怎么用
- 当前MSC治疗AKI仍处于研究阶段,临床决策应基于标准治疗,不推荐常规使用MSC。
局限性
- 人体临床证据仅限于少量早期试验,缺乏疗效确证。
- MSC治疗AKI的知识和技术仍存在关键缺口。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A little over 10 years ago, the therapeutic potential of mesenchymal stromal cells (MSCs) for the treatment of acute kidney injury (AKI) was becoming widely recognized. Since then, there has been further intensive study of this topic with a clear translational intent. Over the past decade, many more animal model studies have strengthened the evidence that systemically or locally delivered MSCs ameliorate renal injury in sterile and sepsis-associated AKI. Some of these preclinical studies have also provided a range of compelling new insights into the in vivo fate and mechanisms of action of MSCs in the setting of AKI and other inflammatory conditions. Coupled with increased knowledge of the functional roles of resident and infiltrating immune cell mediators in determining the severity and outcome of AKI, the progress made in the past decade would appear to have significantly strengthened the translational pathway for MSC-based therapies. In contrast, however, the extent of the clinical experience with MSC administration in human subjects with AKI or sepsis-associated AKI has been limited to a small number of early-phase clinical trials, which appear to demonstrate safety but have not thus far delivered a strong signal of efficacy. In this review, we summarize the most significant new developments in the field of MSC-based therapies as they relate to AKI and reflect on the key gaps in knowledge and technology that remain to be addressed for the true clinical potential of MSCs and, perhaps, other emerging cellular therapies to be realized.
引用
- Fazekas B, Griffin MD. Mesenchymal stromal cell-based therapies for acute kidney injury: progress in the last decade. Kidney Int. 2020. PMID: 32305128. doi:10.1016/j.kint.2019.12.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。